Biogen Inc

+0.59 (+0.28%)
Products, Regulatory

Sage Therapeutics And Biogen Announce 3 Skylark Study Of Zuranolone In Postpartum Depression Met Its Primary And All Key Secondary Endpoints

Published: 06/01/2022 11:54 GMT
Biogen Inc (BIIB) - Sage Therapeutics and Biogen Announce That the Phase 3 Skylark Study of Zuranolone in Postpartum Depression Met Its Primary and All Key Secondary Endpoints.
Sage Therapeutics Inc- Zuranolone 50 Mg Was Generally Well-tolerated and Demonstrated a Safety Profile Consistent With Prior Studies.
Sage Therapeutics Inc- Study of Zuranolone Met All Key Secondary Endpoints With Rapid and Statistically Significant Improvement.
Sage Therapeutics -sage Therapeutics, Biogen Initiated Rolling Submission of NDA to U.S. FDA for Zuranolone,plan to Complete Mdd NDA Filing in H2 2022.
Sage Therapeutics Inc- Associated NDA Filing for Ppd is Anticipated in Early 2023.